

NeuroNEXT Network


Standard Operating Procedure (SOP) Investigational Product Management Version 2.0 SOP NN PM 505

Originators: NeuroNEXT CCC and DCC Personnel

Reviewed and Approved by

Signature and Date:   I approve this document 15-Feb-2023 8:17:38 AM PST 15-Feb-2023 <small>C68AC8DD80334CF982AED1200765F147</small>
Name and Title: Christopher S. Coffey, PhD (DCC Principal Investigator)
Signature and Date:   I approve this document 17-Feb-2023 9:38:36 AM EST 17-Feb-2023 <small>9F8FE4180E504C6AB0A67B835E80C644</small>
Name and Title: Merit E. Cudkowicz, MD MSc (CCC Principal Investigator)
Signature and Date:   I approve this document 15-Feb-2023 8:43:49 PM EST 15-Feb-2023 <small>58FE690F6BCA4F2390E3DA15BCE3F578</small>
Name and Title: Marianne Chase, BA (CCC Senior Director of Clinical Trials Operations)

Signature and Date:

DocuSigned by DIXIE ECKLUND
 | I approve this document
15-Feb-2023 | 11:51:23 AM PST
7006AF622EFC40B6A067A08EC02591B6

15-Feb-2023

Name and Title: Dixie J. Ecklund, RN MSN MBA (DCC Associate Director)

Signature and Date:

DocuSigned by Stacey Grabert
 | I approve this document
22-Feb-2023 | 11:22:05 AM EST
60CC52B0747A44E6B2208D8D880698C0

22-Feb-2023

Name and Title: Stacey Grabert, Pharm.D, MS, (CCC Director of Quality Assurance)

Signature and Date:

DocuSigned by Joan Ohayon
 | I approve this document
15-Feb-2023 | 9:01:37 AM PST
72C6AAFD8CC4485582ACA0700072901A

15-Feb-2023

Name and Title: Joan Ohayon, RN, MSN, CRNP, MSCN (NINDS, NeuroNEXT Program Official)

NN PM 505

NEURONEXT NETWORK STANDARD OPERATING PROCEDURE FOR INVESTIGATIONAL PRODUCT MANAGEMENT

1. POLICY

For all NeuroNEXT Network studies that involve distribution of an Investigational Product (IP) (including drugs, biologics, and devices), no IP will be released to a Clinical Study Site (CSS) prior to Single Institutional Review Board (SIRB) approval of the study and certification from the Clinical Coordinating Center (CCC) that the CSS has been activated for study participation. Once the IP has been released to a CSS, IP inventories will be monitored, and all IP will be accounted for throughout the course of the study. The IP will be handled according to applicable regulations and Protocol Principal Investigator (PPI), SIRB, and funding agency requirements, as well as CSS institutional policies and the Delegation of Responsibilities log for each study.

The IP will be stored in a secure environment, with access limited to key study personnel. The IP will be maintained according to the environmental storage requirements detailed in the protocol, the Investigational Brochure, or other instructions supplied by the IP provider. Only individuals authorized by the study protocol, institutional guidelines, and state law are permitted to dispense IP to study subjects. Procedures for destruction of any unused IP must comply with study protocol, institutional requirements, and applicable Occupational Safety and Health Administration (OSHA) and biohazard materials policies, if appropriate, and only with the express written authorization of the Sponsor or other supplier.

2. SCOPE

This SOP has been developed to be in alignment with federal regulations and Good Clinical Practices (GCP) as set forth in the 2016 Integrated Addendum to ICH E6(R1): Guideline for Good Clinical Practice E6(R2). The policies and procedures described in this SOP apply to the NeuroNEXT CCC and Data Coordinating Center (DCC) within the context of their oversight and advisory roles for the NeuroNEXT Network, and to all NeuroNEXT investigators, staff, subcontractors, or other entities associated with the NeuroNEXT Network who manage, oversee, and conduct research regulated by FDA and/or applicable review committees.

3. ROLES AND RESPONSIBILITIES

The CCC is responsible for ensuring that all necessary approvals have been obtained for the study before any IP is distributed to investigators.

The CSS is responsible for requesting re-stocking of the IP via the on-line interactive web response system created by the DCC, or using a comparable system or process, to ensure that the CSS maintains adequate IP inventory. In certain cases, the DCC and Central Pharmacy may work together to establish minimum/maximum par levels of IP in an effort to automate the re-stocking process. The DCC and/or the Central Pharmacy is responsible for ensuring that investigator requests for IP are processed expeditiously to ensure that CSS have adequate supplies on-hand at all times.

Each CSS investigator is responsible for tracking the disposition of all IP during the course of the study, from the time of receipt to the time of final disposition (e.g. return to the supplier, on-site destruction). This includes a complete accountability/reconciliation of all IP to the participant level.

The DCC Monitors (if contractually agreed upon) are responsible for evaluating the adequacy of IP accountability during routine monitoring.

4. APPLICABLE REGULATIONS AND GUIDELINES

21 CFR 312.6	Labeling of an Investigational New Drug
21 CFR 312.7	Promotion and Charging for Investigational Drugs
21 CFR 312.40	General Requirements for Use of an Investigational New Drug in a Clinical Investigation
21 CFR 312.59	Disposition of Unused Supply of Investigational Drug
21 CFR 312.61	Control of the Investigational Drug
21 CFR 312.69	Handling of Controlled Substances

21 CFR 312.110	Import and Export Requirements
21 CFR 312.160	Drugs for Investigational Use in Laboratory Research Animals or In Vitro Tests
ICH E6, 2.12	The Principles of ICH GCP
ICH E6, 4.6	Investigational Product
ICH E6, 4.7	Randomization Procedures and Unblinding
ICH E6, 5.13	Manufacturing, Packaging, Labeling and Coding Investigational Product(s)
ICH E6, 5.14	Supplying and Handling Investigational Product(s)

5. REFERENCES TO OTHER APPLICABLE SOPS

NN RA 203	Site Regulatory Binder Maintenance
NN SS 401	Site Selection and Qualification
NN SS 402	Site Initiation Visits and Site Training
NN SS 403	Routine Monitoring Visits
NN SS 404	Site Performance Monitoring
NN SS 405	Study Close-out Visits

6. ATTACHMENTS AND REFERENCES

NN PM 505 – A	Document History
---------------	------------------

7. TERMS AND ABBREVIATIONS

The following terms and abbreviations are used in this document:

CCC	Clinical Coordinating Center at Massachusetts General Hospital
CSS	Clinical Study Site(s)
DCC	Data Coordinating Center at The University of Iowa
FDA	U.S. Food and Drug Administration
ICH	International Conference on Harmonisation
IP	Investigational Product(s)
OSHA	Occupational Safety and Health Administration
PPI	Protocol Principal Investigator
SRF	Site Regulatory File
SIRB	Single Institutional Review Board

8. SPECIFIC PROCEDURES

A. Labeling and Release of Investigational Product

#	Who	Task	Attachment	Related SOP
1.	CCC	In collaboration with the PPI or designee, authorize shipment of IP to a Central Investigational Product Distribution Facility (e.g. Central Pharmacy or Manufacturing facility subcontractor) if needed, after contracts are finalized with the Supplier.		

2.	CCC, in collaboration with PPI or designee	In collaboration with the PPI or designee, work with the Central Investigational Product Distribution Facility to finalize product labeling and packaging requirements.		
3.	CCC	Authorize Central Investigational Product Distribution Facility to ship product to CSS when training is completed and applicable regulatory and protocol specific requirements have been fulfilled.		NN SS 401 NN SS 402 NN RA 203
4.	CCC or DCC	Instruct CSS to maintain records containing signed receipts for delivery of IP in their Site Regulatory File (SRF), and provide a copy to the CCC.		NN SS 402

B. Investigational Product Receipt, Storage and Dispensing to Participants

#	Who	Task	Attachment	Related SOP
1.	CCC or DCC	Instruct the CSS Investigator or designee at each site to perform an inventory upon receiving investigational product.		NN SS 402
2.	CCC or DCC	Instruct the investigator or designee to inform the appropriate party if there is missing or damaged IP or other discrepancies (e.g. temperature excursion during shipping).		NN SS 402
3.	CCC or DCC	If there is an urgent need to replace any missing or otherwise discrepant shipment contents, instruct the investigator to contact the appropriate party immediately.		NN SS 402
4.	CCC or DCC	Instruct the CSS to keep all records of drug delivery in the Site Regulatory File (SRF) for review by the Monitor during routine monitoring visits.		NN SS 402
5.	DCC Monitor	Verify proper use (including distribution by protocol-specified randomization schema) of the IP by the CSS during study.		NN SS 403
6.	DCC Monitor	Verify that the IP is stored in an environmentally appropriate and secure location at the CSS, with access restricted to authorized personnel and with appropriate monitoring equipment.		NN SS 403
7.	DCC Monitor	Verify that IP is dispensed or otherwise provided only to participants enrolled in the clinical study.		NN SS 403
8.	DCC Monitor	Verify that the use of the IP occurs under the direct supervision of the investigator or other approved designee(s).		NN SS 403
9.	DCC Monitor	Verify that the product blind is not broken except in the case of an emergency or according to a protocol-defined situation.		NN SS 403
10.	DCC Monitor	If the blind is broken, verify that the PPI and CCC were notified and that the justification is noted in the CSS files.		NN SS 403
11.	DCC Monitor	Document in a "Note to File" for CCC files, the circumstances under which the blind was broken, and any actions taken, if necessary.		NN SS 403
12.	DCC Monitor	Verify that each CSS has accurate and complete records that show receipt and disposition of all IP.		NN SS 403

#	Who	Task	Attachment	Related SOP
13.	DCC Monitor	Verify and reconcile the IP records during periodic monitoring visits.		NN SS 403
14.	DCC and CCC	Document inadequate record-keeping practices, discuss them with the investigator, and report them to the Sponsor.		NN SS 404
15.	CCC and DCC in collaboration with PPI	If a pattern of inadequate inventory management and documentation exists, consider terminating CSS participation in the study.		NN SS 404

C. Investigational Product Accountability and Reconciliation

#	Who	Task	Attachment	Related SOP
1.	DCC	Instruct the CSS that at study conclusion or termination, they must account for all supplies of IP; cross-reference all forms, and follow approved procedure for returning or destroying IP. ¹		NN SS 403 NN SS 405
2.	DCC	Verify and reconcile all investigational product records.		
3.	DCC Monitor	Verify that the CSS has documented and explained any discrepancies in the beginning and ending inventory.		NN SS 405
4.	DCC Monitor	Collect copies of all IP inventory documentation, and provide them to the CCC, where they will be stored with the Trial Master File.		NN SS 405
5.	CSS	Maintain original investigational product inventory documentation in their Regulatory MasterSite Regulatory File.		NN SS 405 NN RA 203
6.	DCC	Instruct CSS to keep IP accountability records for a minimum of seven (7) years, or two (2) years after a marketing application is approved for the product, whichever is longer. CSS should contact the DCC to obtain written permission to destroy records before proceeding with destruction of documentation.		NN SS 405

Note:

¹The CSS must have written authorization from the Sponsor or Sponsor designee (e.g. CCC Project Manager, PPI) to destroy the IP at the CSS.

Certificate Of Completion

Envelope Id: 35C01DD9DFE94E56BC8F0B0889E9BE85 Status: Completed
Subject: Complete with DocuSign: NN PM 505 Investigational Product Management v2.0.docx
Source Envelope:
Document Pages: 6 Signatures: 6 Envelope Originator:
Certificate Pages: 6 Initials: 0 Tania Leeder
AutoNav: Enabled TLEEDER@PARTNERS.ORG
Envelopeld Stamping: Disabled IP Address: 73.123.188.5
Time Zone: (UTC-05:00) Eastern Time (US & Canada)

Record Tracking

Status: Original Holder: Tania Leeder Location: DocuSign
2/15/2023 8:31:55 AM TLEEDER@PARTNERS.ORG

Signer Events

Christopher Coffey christopher-coffey@uiowa.edu Security Level: Email, Account Authentication (Required), Login with SSO
Signature Christopher Coffey
Timestamp Sent: 2/15/2023 8:33:45 AM Viewed: 2/15/2023 11:17:30 AM Signed: 2/15/2023 11:17:40 AM
Signature Adoption: Pre-selected Style
Signature ID: C68AC8DD-8033-4CF9-82AE-D1200765F147
Using IP Address: 128.255.113.139
With Signing Authentication via DocuSign password
With Signing Reasons (on each tab): I approve this document

Electronic Record and Signature Disclosure:
Accepted: 2/15/2023 11:17:30 AM
ID: d8c06eef-74e4-40bf-bed6-fb664c9cb1d2

DIXIE ECKLUND dixie-ecklund@uiowa.edu Security Level: Email, Account Authentication (Required), Login with SSO

DocuSigned by DIXIE ECKLUND
I approve this document 15-Feb-2023 | 11:51:23 AM PST
7006AF622EFC40B6A067A08EC02591B6

Sent: 2/15/2023 8:33:45 AM Viewed: 2/15/2023 2:50:19 PM Signed: 2/15/2023 2:51:24 PM

Signature Adoption: Drawn on Device
Signature ID: 7006AF62-2EFC-40B6-A067-A08EC02591B6
Using IP Address: 128.255.112.230

With Signing Authentication via DocuSign password
With Signing Reasons (on each tab): I approve this document

Electronic Record and Signature Disclosure:
Accepted: 2/15/2023 2:50:19 PM
ID: c6e2fe8f-ba9f-4178-8059-2b8e6442e591

Signer Events	Signature	Timestamp
---------------	-----------	-----------

Joan Ohayon
ohayonj@ninds.nih.gov
Security Level: Email, Account Authentication (Required)

Joan Ohayon

Sent: 2/15/2023 8:33:47 AM
Viewed: 2/15/2023 12:01:23 PM
Signed: 2/15/2023 12:01:40 PM

Signature Adoption: Pre-selected Style
Signature ID:
72C6AAFD-8CC4-4855-82AC-A0700072901A
Using IP Address: 156.40.137.188

With Signing Authentication via DocuSign password
With Signing Reasons (on each tab):
I approve this document

Electronic Record and Signature Disclosure:
Accepted: 2/13/2023 2:03:22 PM
ID: 385a0a53-0f0c-4395-88f6-d5700c36e050

Marianne Chase
MCHASE@mgh.harvard.edu
Sr Director, Clinical Trial Operations
Insight OBO The Massachusetts General Hospital
Security Level: Email, Account Authentication (Required)

Marianne Chase


Sent: 2/15/2023 8:33:46 AM
Viewed: 2/15/2023 8:43:19 PM
Signed: 2/15/2023 8:43:56 PM

Signature Adoption: Pre-selected Style
Signature ID:
58FE690F-6BCA-4F23-90E3-DA15BCE3F578
Using IP Address: 73.114.253.109

With Signing Authentication via DocuSign password
With Signing Reasons (on each tab):
I approve this document

Electronic Record and Signature Disclosure:
Not Offered via DocuSign

Merit Cudkowicz
cudkowicz.merit@mgh.harvard.edu
Chief of Neurology
Security Level: Email, Account Authentication (Required), Logged in


DocuSigned by Merit Cudkowicz

I approve this document
17-Feb-2023 | 9:38:36 AM EST
9F8FE4180E504C6AB0A67B835E80C644

Sent: 2/15/2023 8:33:46 AM
Viewed: 2/17/2023 9:38:26 AM
Signed: 2/17/2023 9:38:38 AM

Signature Adoption: Pre-selected Style
Signature ID:
9F8FE418-0E50-4C6A-B0A6-7B835E80C644
Using IP Address: 68.239.56.73

With Signing Authentication via DocuSign password
With Signing Reasons (on each tab):
I approve this document

Electronic Record and Signature Disclosure:
Accepted: 2/17/2023 9:38:26 AM
ID: 4cc1cfdb-8814-4575-8f6a-02f2f2d79fde

Signer Events	Signature	Timestamp
Stacey Grabert sgrabert@mgh.harvard.edu Director QA Stacey Grabert Security Level: Email, Account Authentication (Required)	 Signature Adoption: Pre-selected Style Signature ID: 60CC52B0-747A-44E6-B220-8D8D880698C0 Using IP Address: 132.183.56.49 With Signing Authentication via DocuSign password With Signing Reasons (on each tab): I approve this document	Sent: 2/15/2023 8:33:46 AM Viewed: 2/22/2023 11:21:55 AM Signed: 2/22/2023 11:22:08 AM
Electronic Record and Signature Disclosure: Accepted: 7/20/2020 8:50:14 AM ID: 5ebadf74-e399-40fd-be82-9c7ca902061b		
In Person Signer Events	Signature	Timestamp
Editor Delivery Events	Status	Timestamp
Agent Delivery Events	Status	Timestamp
Intermediary Delivery Events	Status	Timestamp
Certified Delivery Events	Status	Timestamp
Carbon Copy Events	Status	Timestamp
Witness Events	Signature	Timestamp
Notary Events	Signature	Timestamp
Envelope Summary Events	Status	Timestamps
Envelope Sent	Hashed/Encrypted	2/15/2023 8:33:47 AM
Certified Delivered	Security Checked	2/22/2023 11:21:55 AM
Signing Complete	Security Checked	2/22/2023 11:22:08 AM
Completed	Security Checked	2/22/2023 11:22:08 AM
Payment Events	Status	Timestamps
Electronic Record and Signature Disclosure		

ELECTRONIC RECORD AND SIGNATURE DISCLOSURE

From time to time, Insight OBO The Massachusetts General Hospital (we, us or Company) may be required by law to provide to you certain written notices or disclosures. Described below are the terms and conditions for providing to you such notices and disclosures electronically through the DocuSign system. Please read the information below carefully and thoroughly, and if you can access this information electronically to your satisfaction and agree to this Electronic Record and Signature Disclosure (ERSD), please confirm your agreement by selecting the check-box next to 'I agree to use electronic records and signatures' before clicking 'CONTINUE' within the DocuSign system.

Getting paper copies

At any time, you may request from us a paper copy of any record provided or made available electronically to you by us. You will have the ability to download and print documents we send to you through the DocuSign system during and immediately after the signing session and, if you elect to create a DocuSign account, you may access the documents for a limited period of time (usually 30 days) after such documents are first sent to you. After such time, if you wish for us to send you paper copies of any such documents from our office to you, you will be charged a \$0.00 per-page fee. You may request delivery of such paper copies from us by following the procedure described below.

Withdrawing your consent

If you decide to receive notices and disclosures from us electronically, you may at any time change your mind and tell us that thereafter you want to receive required notices and disclosures only in paper format. How you must inform us of your decision to receive future notices and disclosure in paper format and withdraw your consent to receive notices and disclosures electronically is described below.

Consequences of changing your mind

If you elect to receive required notices and disclosures only in paper format, it will slow the speed at which we can complete certain steps in transactions with you and delivering services to you because we will need first to send the required notices or disclosures to you in paper format, and then wait until we receive back from you your acknowledgment of your receipt of such paper notices or disclosures. Further, you will no longer be able to use the DocuSign system to receive required notices and consents electronically from us or to sign electronically documents from us.

All notices and disclosures will be sent to you electronically

Unless you tell us otherwise in accordance with the procedures described herein, we will provide electronically to you through the DocuSign system all required notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you during the course of our relationship with you. To reduce the chance of you inadvertently not receiving any notice or disclosure, we prefer to provide all of the required notices and disclosures to you by the same method and to the same address that you have given us. Thus, you can receive all the disclosures and notices electronically or in paper format through the paper mail delivery system. If you do not agree with this process, please let us know as described below. Please also see the paragraph immediately above that describes the consequences of your electing not to receive delivery of the notices and disclosures electronically from us.

How to contact Insight OBO The Massachusetts General Hospital:

You may contact us to let us know of your changes as to how we may contact you electronically, to request paper copies of certain information from us, and to withdraw your prior consent to receive notices and disclosures electronically as follows:

To contact us by email send messages to: jhenrique@mgh.harvard.edu

To advise Insight OBO The Massachusetts General Hospital of your new email address

To let us know of a change in your email address where we should send notices and disclosures electronically to you, you must send an email message to us at jhenrique@mgh.harvard.edu and in the body of such request you must state: your previous email address, your new email address. We do not require any other information from you to change your email address.

If you created a DocuSign account, you may update it with your new email address through your account preferences.

To request paper copies from Insight OBO The Massachusetts General Hospital

To request delivery from us of paper copies of the notices and disclosures previously provided by us to you electronically, you must send us an email to jhenrique@mgh.harvard.edu and in the body of such request you must state your email address, full name, mailing address, and telephone number. We will bill you for any fees at that time, if any.

To withdraw your consent with Insight OBO The Massachusetts General Hospital

To inform us that you no longer wish to receive future notices and disclosures in electronic format you may:

- i. decline to sign a document from within your signing session, and on the subsequent page, select the check-box indicating you wish to withdraw your consent, or you may;
- ii. send us an email to jhenrique@mgh.harvard.edu and in the body of such request you must state your email, full name, mailing address, and telephone number. We do not need any other information from you to withdraw consent.. The consequences of your withdrawing consent for online documents will be that transactions may take a longer time to process..

Required hardware and software

The minimum system requirements for using the DocuSign system may change over time. The current system requirements are found here: <https://support.docusign.com/guides/signer-guide-signing-system-requirements>.

Acknowledging your access and consent to receive and sign documents electronically

To confirm to us that you can access this information electronically, which will be similar to other electronic notices and disclosures that we will provide to you, please confirm that you have read this ERSD, and (i) that you are able to print on paper or electronically save this ERSD for your future reference and access; or (ii) that you are able to email this ERSD to an email address where you will be able to print on paper or save it for your future reference and access. Further, if you consent to receiving notices and disclosures exclusively in electronic format as described herein, then select the check-box next to ‘I agree to use electronic records and signatures’ before clicking ‘CONTINUE’ within the DocuSign system.

By selecting the check-box next to ‘I agree to use electronic records and signatures’, you confirm that:

- You can access and read this Electronic Record and Signature Disclosure; and
- You can print on paper this Electronic Record and Signature Disclosure, or save or send this Electronic Record and Disclosure to a location where you can print it, for future reference and access; and
- Until or unless you notify Insight OBO The Massachusetts General Hospital as described above, you consent to receive exclusively through electronic means all notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you by Insight OBO The Massachusetts General Hospital during the course of your relationship with Insight OBO The Massachusetts General Hospital.